Keros Therapeutics, Inc. (KROS) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Stockholders to Contact the Firm to Learn More About the Investigation
NEW YORK, NY / ACCESS Newswire / January 21, 2025 / Bronstein, Gewirtz & Grossman, LLC is investigating potential claims on behalf of purchasers of Keros Therapeutics, Inc. ("Keros" or "the Company") (NASDAQ:KROS). Investors who purchased Keros securities are encouraged to obtain additional information and assist the investigation by visiting the firm’s site: bgandg.com/KROS. Investigation […]